Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications

Tasciotti, Ennio; Liu, Xuewu; Bhavane, Rohan; Plant, Kevin; Leonard, Ashley D.; Price, B. Katherine; Cheng, Mark Ming Cheng; Decuzzi, Paolo; Tour, James M.; Robertson, Fredika M.; Ferrari, Mauro

doi:10.1038/nnano.2008.34

Cited by 631 publications

(534 citation statements)

References 32 publications

Supporting

Mentioning

529

Contrasting

Unclassified

Order By: Relevance

“…At a subsequent stage, MS-MPs were modified through the deposition of a chitosan (CS) coating, thus forming a multifunctional silicon/polymer composite with potential for advanced biomedical applications, a concept that has been recently explored in some recent works [23,24]. The rational behind the selection of CS as the coating polymer was: (i) its know capacity to adsorb to polyactionic surfaces, (ii) its established pharmaceutical record, (iii) and its mucoadhesivess and permeation enhancing properties [25][26][27][28].…”

Section: Introductionmentioning

confidence: 99%

Protein delivery based on uncoated and chitosan-coated mesoporous silicon microparticles

Pastor

Matveeva

Valle-Gallego

et al. 2011

Colloids and Surfaces B: Biointerfaces

View full text Add to dashboard Cite

Mesoporous silicon is a biocompatible, biodegradable material that is receiving increased attention for pharmaceutical applications due to its extensive specific surface. This feature enables to load a variety of drugs in mesoporous silicon devices by simple adsorption-based procedures. In this work, we have addressed the fabrication and characterization of two new mesoporous silicon devices prepared by electrochemistry and intended for protein delivery, namely: (i) mesoporous silicon microparticles and (ii) chitosan-coated mesoporous silicon microparticles. Both carriers were investigated for their capacity to load a therapeutic protein (insulin) and a model antigen (bovine serum albumin) by adsorption. Our results show that mesoporous silicon microparticles prepared by electrochemical methods present moderate affinity for insulin and high affinity for albumin. However, mesoporous silicon presents an extensive capacity to load both proteins, leading to systems were protein could represent the major mass fraction of the formulation. The possibility to form a chitosan coating on the microparticles surface was confirmed both qualitatively by atomic force microscopy and quantitatively by a colorimetric method.Mesoporous silicon microparticles with mean pore size of 35 nm released the loaded insulin quickly, but not instantaneously. This profile could be slowed to a certain extent by the chitosan coating modification. With their high protein loading, their capacity to provide a controlled release of insulin over a period of 60-90 min, and the potential mucoadhesive effect of the chitosan coating, these composite devices comprise several features that render them interesting candidates as transmucosal protein delivery systems.

show abstract

Section: Introductionmentioning

confidence: 99%

Protein delivery based on uncoated and chitosan-coated mesoporous silicon microparticles

Pastor

Matveeva

Valle-Gallego

et al. 2011

Colloids and Surfaces B: Biointerfaces

View full text Add to dashboard Cite

show abstract

“…Porous silicon in particular has long been studied for its potential applications in optoelectronics and sensing as a result of its light-emitting properties [ 6-10 ]. In addition, they can also serve as drug or gene delivery matrix because of their good biocompatibility [11][12] . Porous silicon is typically synthesized by applying a voltage bias to a silicon substrate immersed in an aqueous or ethanoic hydrofluoric acid (HF) solution.…”

mentioning

confidence: 99%

Single Crystalline Mesoporous Silicon Nanowires

et al. 2009

View full text Add to dashboard Cite

Porous semiconductors have garnered significant attention for their novel chemistry and potential applications as high surface area and optically active substrates [ 1-5 ]. Porous silicon in particular has long been studied for its potential applications in optoelectronics and sensing as a result of its light-emitting properties [ 6-10 ]. In addition, they can also serve as drug or gene delivery matrix because of their good biocompatibility [11][12] . Porous silicon is typically synthesized by applying a voltage bias to a silicon substrate immersed in an aqueous or ethanoic hydrofluoric acid (HF) solution. Surface and charge instabilities at the solid-solution interface are thought to nucleate pore formation, and accelerated etching of silicon at the pore tips propagates the voids into the substrate. The resulting pore networks and remaining silicon scaffold form the structure of porous silicon [ 13,14 ]. The synthetic method described in this study, on the other hand, relies on an electroless metal deposition process to provide the current flux necessary for porous silicon formation. Electroless metal deposition and subsequent sacrificial etching of the surrounding silicon lattice has been previously observed [ 15 ] and exploited to controllably etch arrays of silicon nanowires [ 16 ]. We have now found that it is possible to etch arrays of single-crystalline mesoporous silicon nanowires without the application of an external voltage.

show abstract

“…In addition, the biocompatibility and the biodegradation of the NPs must be determined. Our pre-clinical studies demonstrate that the NPs are biodegradable in serum and are not cytotoxic to cultured normal human cells or to tumor cells (2). Th e nanochips are used ex-vivo, with a simple blood draw required to create an individualized proteomic "snapshot" of peptides produced in response to the presence of a specifi c cancer (7).…”

Section: Clinical and Translational Leadsmentioning

confidence: 92%

Nanoporous Silicon as a Platform for Targeted Drug Delivery and Discovery of Proteomic Signatures for Cancer Diagnostics

Tasciotti¹,

Robertson²,

Ferrari³

2008

AACR Education book

View full text Add to dashboard Cite

Th e design of silicon interfaces with controllable nanosized features has opened avenues for development of multiple biomedical applications. To overcome current limitations in the detection and treatment of cancer, we have developed nanoporous silicon chips (nanochips) for identifi cation of protein signatures in biological fl uids and in tandem have designed injectable silicon nanoporous particles (NPs) that provide multi-stage, multi-functional platforms for targeted delivery of therapeutic and contrast agents. Th ese two silicon nanotechnology platforms off er signifi cant advantages in their ability to fi nely tuned their surfaces by biochemical modifi cations. Nanochips provide clinical diagnostic tools for early detection of human disease and for tracking individual patient's responses to treatment regimens. NPs can be designed with specifi c shape, size, pore size and density, and their surfaces modifi ed by conjugation of polyethylene glycol (PEG) of diff erent lengths with fl uorescent characteristics to enhance their circulation time. Further, biological recognition moieties can be conjugated to NPs to allow for their selective targeting. NPs can be loaded with multiple agents including therapeutics, genes, small interfering (si)RNAs and imaging agents such as iron oxide or gadolinium. We believe that the development of these silicon nanoporous platforms are a signifi cant contribution to realizing the goals of personalized medicine. Background and Materials

show abstract

Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications

Cited by 631 publications

References 32 publications

Protein delivery based on uncoated and chitosan-coated mesoporous silicon microparticles

Protein delivery based on uncoated and chitosan-coated mesoporous silicon microparticles

Single Crystalline Mesoporous Silicon Nanowires

Nanoporous Silicon as a Platform for Targeted Drug Delivery and Discovery of Proteomic Signatures for Cancer Diagnostics

Contact Info

Product

Resources

About